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Introduction
Innate immunity is the first line of defense against microor-
ganisms, and is activated when pathogen-recognizing recep-
tors (PRRs) recognize particular molecules that are com-
monly found in microbes.[1] PPRs include membrane-bound
Toll-like receptors (TLRs), cytosolic Nod-like receptors
(NLRs), and RIG-I family proteins. Common microbial
components recognized by PRRs include bacterial peptido-
glycan (PGN), lipopolysaccharide (LPS), lipoproteins, flag-
ellin, DNA, RNA, and also viral RNA. PGN is a component
of the bacterial cell wall, and consists of polysaccharide
chains linked to peptides. The polysaccharide is a b ACHTUNGTRENNUNG(1–4)
glycan composed of alternating N-acetylglucosamine
(GlcNAc) and N-acetylmuramic acid (MurNAc); the car-
boxyl group of MurNAc is the point of linkage to the pep-
tide. At the branched position of the peptide, there is usual-
ly a diaminocarboxylic acid, such as l-Lys (in Gram-positive
bacteria) or meso-diaminopimelic acid (meso-DAP, in
Gram-negative bacteria and some Gram-positive bacteria).
PGN has been known as a potent immunostimulator and an
immune adjuvant. Recently, Inohara et al. and Philpott et al
independently showed that the intracellular protein Nod1,
which is the founding member of the NLR protein family, is
a receptor against PGN fragments (muropeptides).[2,3] Phil-
pott et al. reported that Nod1 senses DAP-containing muro-
peptides, such as GlcNAc-MurNAc-l-Ala-g-d-Glu-meso-
DAP,[2] whereas we showed a DAP-containing smaller pep-
tide, iE-DAP (g-d-glutamyl diaminopimelic acid), activates
Nod1 by using PGN synthetic peptide fragments.[3] It was
also shown that meso-DAP itself activates Nod1 of human
Abstract: Bacterial cell wall peptido-
glycan (PGN) is a potent immunosti-
mulator and immune adjuvant. The
PGN of Gram-negative bacteria and
some Gram-positive bacteria contain
meso-diaminopimelic acid (meso-
DAP), and we have recently shown
that the intracellular protein Nod1 is a
PGN receptor and recognizes DAP-
containing peptides. In this study, we
achieved the synthesis of DAP-contain-
ing PGN fragments, including the first
chemical synthesis of tracheal cytotoxin
(TCT), GlcNAc-(b1–4)-(anhydro)Mur-
NAc-l-Ala-g-d-Glu-meso-DAP-d-Ala,
and a repeating-unit of DAP-type
PGN, GlcNAc-(b1–4)-MurNAc-l-Ala-
g-d-Glu-meso-DAP-d-Ala. For the syn-
thesis of PGN fragments, we first es-
tablished a new synthetic method for
an orthogonally protected meso-DAP
derivative, and then we constructed the
glycopeptide structures. The ability of
these fragments to stimulate human
Nod1, as well as differences in Nod1
recognition of the variety of synthe-
sized ligand structures were examined.
The results showed that the substitu-
tion of the N terminus of iE-DAP is
necessary for stronger Nod1 recogni-
tion, but the structure of the substitu-
ent seems not to be strictly recognized.
The importance of the carboxyl group
at the 2-position of DAP for human
Nod1 stimulation was also shown.
Keywords: carbohydrates ·
immunochemistry · peptides ·
tracheal cytotoxin
[a] Dr. A. Kawasaki, Y. Karasudani, Y. Otsuka, Dr. Y. Fujimoto,
Prof. K. Fukase





[b] Dr. M. Hasegawa, Prof. N. Inohara
Department of Pathology
The University of Michigan Medical School
Ann Arbor, MI 48109 (USA)
[c] Prof. N. Inohara
Department of Biochemistry 2nd
Interdisciplinary Graduate School of Medicine and Engineering
University of Yamanashi
Yamanashi, 409-3898 (Japan)
 2008 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Chem. Eur. J. 2008, 14, 10318 – 1033010318
epithelial cells from various tissues.[4] Another intracellular
protein, Nod2, recognizes PGN with a muramyl dipeptide
(MDP) structure.[5,6]
Our recent findings showed that Gram-negative bacteria
and certain Gram-positive bacteria that have DAP-type
PGN secrete Nod1 ligands to the environment,[7] and the
immune system seems to be regulated by the level of these
ligands. Genetic studies have linked polymorphisms in the
human Nod1 gene with susceptibility to several diseases, in-
cluding allergic diseases, such as asthma,[8–10] Crohns dis-
ease,[11] and sarcoidosis.[12] However, the function and immu-
nostimulatory mechanism of Nod1 are not yet well under-
stood. Although we found potent synthetic Nod1 ligands in-
cluding N-myristoyl-iE-DAP (KF-1B) for in vivo analysis,
which enabled the investigation of the Nod1 function,[13,14] it
is also essential to understand the natural Nod1 ligands con-
sidered to be released into the environment.
It is often difficult to purify bacterial glycoconjugates,
such as PGN fragments, from natural sources, because they
are usually heterogeneous. In addition, the possibility of
contamination of other immunostimulatory compounds
cannot be eliminated even after extensive purification. We
have thus synthesized a series of the PGN fragments, includ-
ing Lys-type fragments found normally in Gram-positive
bacteria, to study the key molecules in immune-system acti-
vation, and to determine the functions of ligands and recep-
tors.[15,16] The repeating unit of DAP-type PGN, GlcNAc-
(b1–4)-MurNAc-l-Ala-g-d-Glu-meso-DAP-d-Ala 1, how-
ever, has not been chemically synthesized, although the syn-
thesis of monosaccharide DAP-type fragments has been per-
formed.[17,18]
Tracheal cytotoxin (TCT) 5 was originally found as a se-
cretion of Bordetella pertussis, the causative agent of pertus-
sis (whooping cough).[19] The structure of TCT was then de-
termined as identical with GlcNAc-(anhydro)MurNAc-l-
Ala-g-d-Glu-meso-DAP-d-Ala.[20] It is a naturally occurring
DAP-containing fragment of Gram-negative peptidoglycan,
and considered as a potent stimulator of the innate immune
response. TCT shows a variety of immunological activities,
including immune stimulation in hamster tracheal epithelial
cells,[21] activation of peptidoglycan recognition protein LC
(PGRP-LC) in Drosophila to trigger an innate immune re-
sponse,[22,23] and stimulation of the murine (but scarcely in
human) immune system by Nod1.[24] TCT used in biological
studies has been derived only from natural sources, and it
has not been chemically synthesized.
In this study, we synthesized DAP-type PGN repeating
unit 1, its fragments 2, 3, and 4, and tracheal cytotoxin
(TCT) 5 and its fragments 6, 7, and 8 to investigate their
biological functions, including stimulation of NLR. To ach-
ieve the synthesis of these DAP-containing PGN fragments,
a differently protected meso-DAP is necessary. The synthe-
ses of some alternatively protected meso-DAPs have been
reported by several groups,[18, 25–37] as reviewed by Dzierz-
bicka.[38] In this study, two chiral fragments were coupled to
prepare the DAP backbone. We have previously studied the
biological activities of DAP isomers, which include the three
DAP isomers: meso-, (2S,6S)-, and (2R,6R)-DAP[4] as well
as four iE-DAP isomers: (2R,6R)-, (2R,6S)-, (2S,6R)-, and
(2S,6S)-DAP.[13] The peptide, which containes the natural
(2S,6R)-meso-DAP structure, showed the most potent Nod1
stimulatory activity. Establishing the efficient synthesis
methods for these PGN fragments would lead to the new
analogues with potent agonistic or antagonistic activities,
and new molecular probes for the elucidation of biological
function.
Results and Discussion
We synthesized meso-DAP-containing PGN fragments, in-
cluding the repeating-unit of DAP-type PGN 1 and tracheal
cytotoxin (TCT) 5. We have previously synthesized Lys-type
PGN fragments containing muramyl dipeptide (MDP;
MurNAc-l-Ala-d-isoGln), which is recognized by intracellu-
lar receptor Nod2. In this study, we focused on DAP-con-
taining PGN fragments and their Nod1 stimulatory activi-
ties. The difference between saccharide moieties MurNAc
and (anhydro)MurNAc is also of interest due to their effect
on the receptor recognition. For the synthesis of these frag-
ments, we first established a synthetic method for the or-
thogonally protected meso-DAP.
To prepare the meso-DAP backbone, we coupled two a-
amino acid derivatives, maintaining both chiral centers. We
first attempted to use the Wittig reaction with several com-
binations of the intermediates (eg. Garners aldehyde[39] and
the corresponding bromide), but most of these reactions
yielded an epimeric mixture of the compounds. We then
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used Kocienski-modified Julia olefination (Scheme 1),[40] uti-
lizing an aldehyde 9[41] and a sulfone 10,[42] both of which
were derived from d-serine. The reaction proceeded without
epimerization to give the key intermediate 11, which was
converted to the protected meso-DAP 12 and 13. Compound
12 was then used for the preparation of the tripeptide (l-
Ala-g-d-Glu-meso-DAP), and 13 was used for the tetrapep-
tide (l-Ala-g-d-Glu-meso-DAP-d-Ala).
The synthesis of the protected meso-DAP 17 for the prep-
aration of the tripeptide is shown in Scheme 2. The Julia–
Kocienski reaction of sulfone 10 with aldehyde 9, carried
out with sodium hexamethyldisilazide (NaHMDS) in THF
at 70 8C, gave the key intermediate 11 in 71 % yield. Once
compound 17 had been formed, we used chiral HPLC analy-
sis (CHIRALPAK AD-H, Daicel Chemical) to confirm that
no epimerization had occurred in comparison with other
epimers.[4] For the synthesis of the meso-DAP derivative for
tripeptide preparation, two carboxylic acids can be protect-
ed with the same benzyl esters as in compound 17. Hence,
after cleavage of two isopropylidene aminals of 11 with p-
toluenesulfonic acid (pTsOH), reprotection of the cleaved
amino group with a tert-butoxycarbonyl (Boc) group, and re-
duction of the double bond with H2 under Pd/C, both hy-
droxy groups of 15 were oxidized with pyridinium dichro-
mate (PDC) to carboxyl groups to give 16. Selective reduc-
tion of the double bond in the presence of the benzyloxycar-
bonyl (Z) group in 14 was attempted with Pd/Fib,[43] but the
result was not satisfactory. Thus, the deprotected amino
group was reprotected with benzyl chloroformate (ZCl).
Esterification of 16 with benzyl bromide (BnBr) and
Cs2CO3 in DMF gave fully protected meso-DAP 17.
The synthesis of the protected meso-DAP 25 for the prep-
aration of the tetrapeptide is shown in Scheme 3. The iso-
propylidene groups and the Boc group of 11 were cleaved
with 1 m HCl in MeOH, and monocarbamate formation at
the liberated amino group with triphosgene and triethyla-
mine (Et3N) in CH2Cl2 gave 18. Subsequent reduction and
reprotection of the amino group with the Z group yielded
compound 19. The hydroxy group of 19 was oxidized to car-
boxylic acid 20 with RuCl3·nH2O and NaIO4 in acetone/
H2O 1:1, and esterification by using acetyl chloride (AcCl)
in methanol under acidic conditions gave compound 21. The
Boc group was introduced to the NH group of the carba-
mate by using di-tert-butyl dicarbonate (Boc2O), N,N-dime-
thylaminopyridine (DMAP), and Et3N, and the carbamate
and ester were cleaved with LiOH to give 23. For parts of
the molecule in which the carbamate was protected with a Z
group or there was no protecting group at the carbamate
Scheme 1. Synthesis of orthogonally protected meso-DAP.
Scheme 2. Synthesis of meso-DAP derivative 17: a) NaHMDS, 9, THF,
70 8C, 71%; b) pTsOH·H2O; c) Boc2O, sat. NaHCO3 aq., MeOH, 92%;
d) Pd/C, H2, THF; e) ZCl, Et3N, 58 % (for two steps); f) PDC, DMF;
g) BnBr, Cs2CO3, DMF, 61 % (for two steps).
Scheme 3. Synthesis of meso-DAP derivative 25 : a) 1n HCl in MeOH;
b) triphosgene, Et3N, CH2Cl2, 22% (for two steps); c) Pd/C, H2, MeOH;
d) ZCl, NaHCO3, 1,4-dioxane/H2O 1:1, 82% (for two steps);
e) RuCl3·n H2O, NaIO4, acetone/H2O 1:1, 66%; f) AcCl, MeOH, 89%;
g) Boc2O, DMAP, Et3N, THF, 86%; h) LiOH, THF/H2O 3:1;
i) 1) Cs2CO3, MeOH; 2) BnBr, DMF, 83% from 22 ; j) PDC, DMF, 86%.
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ring, the ring-opening reaction under basic conditions did
not proceed, and cleavage of the Z group occurred. The li-
berated carboxyl group of 23 was derivatized to a benzyl
ester to give 24, and oxidation of the hydroxy group of 24
afforded the alternatively protected meso-DAP 25.
The peptide moieties, tripeptide 28 and tetrapeptide 30,
were synthesized as shown in Scheme 4. For the preparation
of tripeptide 28, the Boc group of protected meso-DAP 17
was cleaved with trifluoroacetic acid (TFA), and the depro-
tected peptide was coupled to the side-chain carboxyl group
of Boc-d-Glu-OBn by using 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide hydrochloride (WSCI·HCl), 1-hydroxy-
benzotriazole (HOBt), and triethylamine in THF to give 26.
l-Alanine was introduced in a similar manner, and depro-
tection of the N-terminal Boc group gave tripeptide 28. Tet-
rapeptide 30 was synthesized in a similar manner by starting
from 25. With these DAP-containing peptides in hand, we
proceeded to the synthesis of the glycan (Scheme 5) and as-
sembly of the peptidoglycan fragments (Scheme 6).
The anhydro-saccharides 34 and 40 were synthesized as
shown in Scheme 5. Treatment of 1,6-anhydro sugar 31[44,45]
with NaH followed by addition of trifluoromethanesulfonyl-
(S)-2-propionic acid ethyl ester afforded Mur ACHTUNGTRENNUNG(anh) deriva-
tive 32. The azide group of 32 was reduced with Zn in THF/
AcOH, and subsequent acetylation gave compound 33.
Cleavage of the ethyl ester gave 1,6-anhydro-muramic acid
derivative 34. For disaccharide 40, the benzyl and azide
groups of 32 were reduced by hydrogenation under H2
(15 kgcm2) with Pd(OH)2 in THF to give 35. The liberated
amino group was then protected with a 2,2,2-trichloroethoxy-
carbonyl (Troc) group. The resulting compound 36 was uti-
lized for the glycosylation with imidate 37 by using trime-
thylsilyl trifluoromethanesulfonate (TMSOTf) and molecu-
lar sieves (MS, 4 ) in CH2Cl2, at 15 8C, and gave the di-
saccharide 38. When the N-acetylted acceptor was used for
the glycosylation in place of 36, the yield of glycosylation
Scheme 4. Synthesis of the tripeptide 28 and tetrapeptide 30 : a) TFA;
b) HCl in Et2O; c) Boc-d-Glu-OBn, WSCD·HCl, HOBt, Et3N, THF;
d) Boc-l-Ala-OH, WSCD·HCl, HOBt, Et3N, THF; e) HCl·H-d-Ala-
OBn, WSCD·HCl, HOBt, Et3N, THF.
Scheme 5. Synthesis of anhydro-saccharides 34 and 40 : a) NaH, CH2Cl2, 78 %; b) Zn, THF/AcOH 1:1; c) Ac2O/pyridine 1:1, 79% for two steps;
d) LiOH, THF/1,4-dioxane/H2O 4:2:1, 44 %; e) H2 (15 kg cm
2), Pd(OH)2, THF; f) TrocCl, Et3N, CH2Cl2, 77 % for two steps; g) TMSOTf, MS (4 ),
CH2Cl2, 15 8C, 30 min, 65 %; h) Zn/Cu, AcOH/THF/Ac2O 1:1:1, 81%; i) LiOH, THF/1,4-dioxane/H2O 4:2:1, quant.
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was 37 %. The obtained compound 38 was then treated with
Zn/Cu in THF/acetic acid/acetic anhydride to cleave the N-
Troc groups and acetylate the liberated amino groups. Sub-
sequent deprotection of the ester group afforded disacchride
40.
The syntheses of 5 (TCT), 6, 7, and 8, which contain anhy-
dro-muramic acid are shown in Scheme 6. Monosaccharide
34 and disaccharide 40 were condensed with tripeptide 28
and tetrapeptide 30 independently, by using WSCI·HCl,
HOBt, and triethylamine to give protected disaccharide tet-
rapeptide 41 (92 %), disaccharide tripeptide 42 (85 %), mon-
osaccharide teterapeptide 43 (95 %), and monosaccharide
tripeptide 44 (75 %). All benzyl and benzyloxycarbonyl
groups of 41, 42, 43, and 44 were removed by catalytic hy-
drogenation with Pd(OH)2 and H2 to give 5 (TCT), 6, 7, and
8, respectively. We thus achieved the first chemical synthesis
of TCT.
The series of DAP-type peptidoglycan fragments were
also synthesized as shown in Schemes 7 and 8. The monosac-
charide fragments 3 and 4 were synthesized from 45[15]
(Scheme 7). The isomerization of the allyl group of 45 to a
vinyl group was performed with H2-activated [Ir ACHTUNGTRENNUNG(cod)-ACHTUNGTRENNUNG(MePh2P)2]PF6 (cod=1,5-cyclooctadiene) to give compound
46.[15,46] The ethyl ester of 46 was cleaved with LiOH in 1,4-
dioxane/THF/H2O 2:4:1, and tripeptide 28 or tetrapeptide
30 was subsequently introduced to the liberated carboxylic
acid by using WSCD·HCl, HOBt, and triethylamine, to give
48 and 49, respectively. The cleavage of the vinyl group with
iodine and water gave 50 and 51.[47] All remaining protecting
groups, the benzyl groups in the peptide moiety, and the
benzylidene group at the 4,6-position of the glycan, were
cleaved by hydrogenation using Pd(OH)2 catalysis to give
compounds 3 and 4.
Disaccharide tetrapeptide 1 and disaccharide tripeptide 2
were then synthesized from 52[15,16] (Scheme 8), in a similar
manner as used for the monosaccharides 3 and 4. First, 53
was obtained by deprotection of the N-Troc groups of 52
and subsequent one-pot acetylation of the liberated amino
groups with Zn/Cu in THF/AcOH/Ac2O. Isomerization of
the allyl group with Ir complex,
and hydrolysis of ethyl ester
gave 55. Peptide coupling with
tripeptide 28 or tetrapeptide 30,
cleavage of their vinyl groups
with I2 and H2O, and final de-
protection afforded disacchar-
ide with tripeptide 1 and disac-
charide with tetrapeptide 2, re-
spectively. This synthesis of 1 is
the first chemical synthesis of a
repeating unit of DAP-type
PGN.
The human Nod1 stimulating
activity of each synthetic pepti-
doglycan fragment was then
evaluated by HEK293T bioas-
say as previously described[3]
(Figures 1 and 2). First, the anhydro-muramic acid contain-
ing compounds 5 (TCT) and 6 (DS ACHTUNGTRENNUNG(anh)-3PDAP) were exam-
ined in comparison with shorter Nod1 ligands, A-iE-DAP
(l-Alanyl-g-d-glutaminyl-diaminopimelic acid)[14] as shown
in Figure 1.
In these compounds, 5 (TCT) showed only very weak
human-Nod1 stimulatory activity. These data are consistent
with a report that utilized TCT from a natural source.[24] On
the other hand, 6 (DS ACHTUNGTRENNUNG(anh)-3PDAP) showed approximately
10-fold higher activity than that of A-iE-DAP. This demon-
strated that the difference of one d-alanine residue attached
to DAP has a strong affect on recognition by human Nod1.
Scheme 6. The synthesis of tracheal cytotoxin (TCT) and other fragments: a) WSCD·HCl, HOBt, Et3N, DMF;
b) Pd(OH)2, H2 (20 kg cm
2), THF.
Scheme 7. Synthesis of monosaccharide-tetrapeptide 3 and -tripeptide 4 :
a) [IrACHTUNGTRENNUNG(cod)(H) ACHTUNGTRENNUNG(MePh2P)2]PF6, THF, 91%; b) LiOH, THF/1,4-dioxane/
H2O 4:2:1, quant.; c) WSCD·HCl, HOBt, Et3N, DMF; d) I2, THF/H2O
1:1; e) Pd(OH)2, H2 (20 kg cm
2), AcOH.
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A free carboxyl group at the 2-position of DAP is, therefore,
favorable for the receptor recognition.
We then examined the Nod1 stimulatory activity of the
PG fragments, 1 (DS-4PDAP), 2 (DS-3PDAP), 3 (MS-4PDAP),
and 4 (MS-3PDAP), in comparison with the anhydro-
MurNAc-containing 6 (DS ACHTUNGTRENNUNG(anh)-3PDAP), A-iE-DAP, and a
known potent ligand, C14-iE-DAP (KF1B; N-myristoyl-iE-
DAP;[14] Figure 2). This also showed similar tendencies to
the activity determined by peptide structure, with tripeptide
compounds (2 and 4) being stronger human Nod1 stimula-
tors than tetrapeptide compounds (1 and 3). Among these
fragments, 4 (MS-3PDAP) showed the most potent activity,
which was similar to that of 6 (DSACHTUNGTRENNUNG(anh)-3PDAP) and C14-iE- DAP (KF1B). These results suggested that the substitutionof the N-terminus of iE-DAP is necessary for stronger Nod1recognition, but the structure of the substituent seems not tobe strictly recognized. The importance of the carboxyl groupat the 2-position of DAP for the Nod1 stimulation is alsoshown by these results. It has previously been observed that3 (MS-4PDAP) and 4 (MS-3PDAP) showed similar activities inthe human Nod1 stimulation at a higher concentration(5 mm).[48] Although we also observed that 3 (MS-4PDAP) and4 (MS-3PDAP) showed similar stimulatory activities at ahigher concentrations, such as 1000 ngmL1 (1.4–1.6 mm), de-
Scheme 8. Synthesis of a DAP-type PGN repeating unit 1 and the fragments 2 : a) Zn/Cu, THF/AcOH/Ac2O 1:1:1, 46%; b) [Ir ACHTUNGTRENNUNG(cod)(H)ACHTUNGTRENNUNG(MePh2P)2]PF6,
THF, 80%; c) LiOH, THF/1,4-dioxane/H2O 4:2:1; d) WSCD·HCl, HOBt, Et3N, DMF; e) I2, THF/H2O 1:1; f) H2 (20 kg cm
2), Pd(OH)2, AcOH.
Figure 2. Stimulation of Nod1 by PG fragments, A-iE-DAP(l-Alanyl-g-d-
glutamyl-diaminopimelic acid), C14-iE-DAP (KF1B; N- myristoyl-iE-
DAP), 1 (DS-4PDAP), 2 (DS-3PDAP), 3 (MS-4PDAP), 4 (MS-3PDAP), and 6
(DS ACHTUNGTRENNUNG(anh)-3PDAP). HEK293T cells were transfected with human-Nod1,
and the indicated amount of each compound was added to the cells and
the ability of each compound to activate NF-kB was determined by luci-
ferase reporter assay.[7]
Figure 1. Stimulation of Nod1 by PG fragments, A-iE-DAP (l-Alanyl-g-
d-glutamyl-diaminopimelic acid), 5 (TCT), and 6 (DS ACHTUNGTRENNUNG(anh)-3PDAP).
HEK293T cells were transfected with human-Nod1, and the indicated
amount of each compound was added to the cells and the ability of each
compound to activate NF-kB was determined by luciferase reporter
assay.[7] ~: 6, ^: TCT (5) *: A-iE-DAP.
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tailed Nod1 stimulatory activities were observed at relative-
ly lower doses from 0.1 to 100 ngmL1 in this study.
Conclusion
As described, we have developed a new method for the
preparation of orthogonally protected meso-DAP, and ach-
ieved the first chemical synthesis of TCT and the repeating-
unit of DAP-type PGN, and various other DAP-type PGN
partial structures, to investigate the PGN-receptor recogni-
tion. We determined human Nod1 stimulatory activities with
these synthetic fragments. The results demonstrated that the
free carboxyl group at the 2-position of DAP is important
for human Nod1 stimulation, and that substitution of the N
terminus of iE-DAP is recognized by Nod1, although this
seems not to be a strict recognition. TCT only weakly stimu-
lates human Nod1, but it has been reported that TCT has a
key role in innate immune systems of other species.[22, 23]
One of these examples is the activation of PGRP-LC in
Drosophila,[22, 23] which is a trigger for its innate immune re-
sponse against Gram-negative bacteria. It was also recently
shown that recognition of DAP-type PGN by PGRP-LE in
Drosophila was crucial for the induction of autophagy,
which prevented the intracellular growth of Listeria mono-
cytogenes and promoted host survival after the infection.[49]
The structurally defined synthesized PGN fragments should
contribute to further understanding of the mechanism of
PGN action in the immune system.
Experimental Section
General procedures : 1H NMR spectra were recorded at 400 MHz by
using a JEOL JMN-GSX 400 spectrometer and at 500 MHz by using a
JEOL JNM-LA 500 spectrometer. The chemical shifts in CDCl3 are
given in d values from tetramethylsilane as an internal standard. For the
measurement in D2O, the HDO signal (d=4.718 ppm at 30 8C) was used
as a reference. ESI-TOF mass spectrometry was carried out by using an
Applied Biosystem Mariner Biospectrometry Workstation. ESI-QTOF
mass spectrometry was carried out by using a Waters-Micromass Q-Tof
micro. Elemental analyses were performed with Yanaco CHN corder
MT-6. Silica-gel column chromatography was carried out by using Kiesel-
gel 60 (Merck, 0.040–0.063 mm) at medium pressure (2–4 kg cm2).
HPLC analysis was carried out with CHROMATOPAC C-R7A plus and
LCsolution by SHIMADZU CORPORATION. Anhydrous CH2Cl2 was
prepared by distillation from calcium hydride. Molecular sieves 4  were
activated in vacuo at 250 8C for 3 h before use. All other reagents and
solvents used were purchased from commercial sources.
1-[(4R)-2,2-Dimethyl-3-N-benzyloxycarbonyloxazolidin-4-yl]-3-[(4S)-2,2-
dimethyl-3-N-tert-butyloxycarbonyloxazolidin-4-yl]-1-propene (11):
NaHMDS (7.7 mL, 1.0m in THF) was added dropwise to a solution of 10
(2.7 g, 5.90 mmol) in dry THF (50 mL) at 70 8C. Then aldehyde 9 (1.4 g,
5.90 mmol) in dry THF (10 mL) was added, and the resulting mixture
was stirred for 2 h at RT. After this time, the reaction was extracted with
Et2O. The organic layer was washed with brine, dried over Na2SO4, and
then concentrated in vacuo. The residue was purified by silica-gel flash
chromatography (150 g, toluene/AcOEt 15:1) to give 11 (2.1 g, 75%).
1H NMR (500 MHz, CDCl3): d=7.40–7.28 (5 H, m; C6H5), 5.56–5.38
(2 H, m;CH=CH), 5.09 (2 H, br s;CH2Ph), 4.11–4.05 (1 H, m; C=C
CH), 3.90–3.57 (5 H, m; CHCH2C=C-, OCH2CH  2), 2.53–
1.96 (2 H, m; CH2C=C), 1.63–1.48 ppm (7 H, m; CH3 7); elemental
analysis calcd (%) for C26H38N2O6·0.9H2O: C 63.63, H 8.17, N 5.71;
found: C 63.28, H 7.91, N 6.18; ESI-TOF-MS (positive): m/z : 475.1
[M+H]+ .ACHTUNGTRENNUNG(2R,6S)-2-(Benzyloxycarbonylamino)-6-(tert-butyloxycarbonylamino)-
hept-3-ene-1,7-diol (14): pTsOH·H2O (2 g, 0.011 mol) was added to a so-
lution of 11 (2.4 g, 5.05 mmol) in MeOH, and the resulting mixture was
stirred for 3 h. After this time, saturated NaHCO3 aq. was added to bring
the mixture to pH 8 and then Boc2O (1.2 mL, 5.05 mmol) was added.
After the mixture had been stirred for 5 h, it was extracted with CHCl3.
The organic layer was washed with brine, dried over Na2SO4, and then
concentrated in vacuo. The residue was purified by silica-gel flash chro-
matography (150 g, CHCl3/acetone 5:1) to give 14 (1.7 g, 89%).
1H NMR
(500 MHz, CDCl3): d=7.37–7.29 (5 H, m; C6H5), 5.54 (1 H, td, J =10,
5 Hz; CH2CH=CH, cis), 5.40 (1 H, t, J=10 Hz; CH2CH=CH,
cis), 5.11 (1 H, d, J =12 Hz; C6H5CH2), 5.05 (1 H, d, J =12 Hz; C6H5
CH2), 4.54 (1 H, br s; HNCHCH2), 3.67–3.59 (4 H, m; CH2OH
 2), 3.55–3.53 (1 H, m; =CHCH), 2.29–2.24 (2 H, m; CH2CH=),
2.14–1.62 (2 H, m; CH2OH  2), 1.44 ppm (9 H, s; (CH3)3C); elemental
analysis calcd (%) for C20H30N2O6: C 60.90, H 7.67, N 7.10; found: C
63.28, H 7.91, N 6.18; ESI-TOF-MS (positive): m/z : 395.2 [M+H]+ .ACHTUNGTRENNUNG(2S,6R)-6-(Benzyloxycarbonylamino)-2-(tert-butyloxycarbonylamino)-
heptane-1,7-diol : Compound 14 (1.57 g, 3.99 mmol) was dissolved in
THF (40 mL) and Pd/C (1.5 g) was added to the resulting solution. The
reaction was stirred for 1 day under a H2 atmosphere. After this time, Pd/
C was removed by membrane filtration and the solution was concentrat-
ed in vacuo. The residue was dissolved in 1,4-dioxane (20 mL) at 0 8C,
and then NaHCO3 aq. (1.3 g, 0.016 mol, 20 mL) and ZCl (855 mL,
5.99 mol) were added. The mixture was stirred for 30 min at RT. After
this time, the reaction mixture was extracted with AcOEt. The organic
layer was washed with saturated NaHCO3 aq. and brine, dried over
Na2SO4, and then concentrated in vacuo. The residue was recrystallized
by CHCl3/hexane to give 15 (869 mg, 58 %).
1H NMR (500 MHz, CDCl3):
d=7.38–7.29 (5 H, m; C6H5), 5.10 (2 H, s; C6H5CH2), 3.72–3.3.61
(4 H, m; CH2OH  2), 3.54–3.52 (2 H, m; aH  2), 2.03 (2 H, m;
CH2OH  2), 1.64–1.56 (4 H, m; CHCH2CH2  2), 1.44 (9 H, s;
(CH3)3C), 1.33–1.23 ppm (2 H, m; CH2CH2CH2); elemental analy-
sis calcd (%) for C20H32N2O6: C 60.59, H 8.14, N 7.07; found: C 60.51, H
8.02, N 7.12; ESI-TOF-MS (positive): m/z : 397.3 [M+H]+ .
Dibenzyl (2S,6R)-6-(benzyloxycarbonylamino)-2-(tert-butyloxycarbonyla-
mino)heptanedioate (17): Compound 15 (420 mg, 1.06 mmol), PDC (4 g,
0.011 mol), and Celite (4 g) were added to dry DMF (15 mL), and the re-
sulting mixture was stirred for 1 day. After this time, the mixture was fil-
trated through Celite, and the filtrate was extracted with Et2O. The or-
ganic layer was washed with 10 % citric acid solution, dried over Na2SO4,
and then concentrated in vacuo. The residue and Cs2CO3 (363 mg,
1.11 mmol) were dissolved in MeOH (5 mL) and the solution was con-
centrated in vacuo. The residue was dissolved in dry DMF (10 mL) and
then BnBr (265 mL, 2.23 mmol) was added under an Ar atmosphere.
After the reaction had been stirred for 1 day, it was extracted with
AcOEt. The organic layer was washed with brine, dried over Na2SO4,
and then concentrated in vacuo. The residue was purified by silica-gel
flash chromatography (40 g, toluene/AcOEt 8:1) to give 17 (475 mg,
74%). 1H NMR (500 MHz, CDCl3): d =7.35–7.28 (5 H, m; C6H5), 5.28
(1 H, br s; NH), 5.17–5.07 (6 H, m; CH2Ph  3), 4.98 (1 H, br s; NH),
4.36 (1 H, d, J =5 Hz; aH), 4.28 (1 H, d, J =4 Hz; aH), 1.56–1.26 (6 H, m;
ACHTUNGTRENNUNG(CH2)3), 1.42 ppm (9 H, s; CACHTUNGTRENNUNG(CH3)3); elemental analysis calcd (%)
for C34H40N2O8·0.3 H2O: C 66.94, H 6.71, N 4.59; found: C 66.95, H 6.60,
N 4.45; HPLC analysis: (Daicel CHIRAL PAK AD-H, 0.46  25 cm,
1 mL min1, hexane/2-propanol 7:3): 254 nm; ESI-TOF-MS (positive):
m/z : 605.3 [M+H]+ .
(4S)-4-[(4R)-4-(Benzyloxycarbonyamino)-5-hydroxy-2-pentenyl]oxazoli-
dine-2-one (18): Compound 11 (700 mg, 1.48 mmol) was dissolved in
MeOH (9 mL) and added to 4 n HCl in 1,4-dioxane (3 mL). After the re-
action mixture had been stirred for 1.5 h, it was concentrated in vacuo.
The residue was dissolved in dry CH2Cl2 (14 mL) at 0 8C, and then Et3N
(1 mL, 7.40 mmol) was added. A solution of triphosgene (158 mg,
0.53 mmol) in CH2Cl2 (7 mL) was added to the mixture, and it was stirred
for a further 1 h. After this time, the reaction mixture was quenched by
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saturated NaHCO3 aq. The organic layer was washed with saturated
NaHCO3 aq., dried over Na2SO4, and then concentrated in vacuo. The
residue was purified by silica-gel flash chromatography (50 g, CHCl3/ace-
tone 2:1) to give 18 (387 mg, 82%). 1H NMR (500 MHz, CDCl3): d=
7.37–7.27 (5 H, m; C6H5), 5.61–5.51 (2 H, m; CH=CH), 5.13–5.06
(2H, s; CH2Ph), 4.59–4.44 (2H, m; C=CCH, C(O)OCH2CH),
4.02–3.99 (1 H, m; C(O)OCH2CH), 3.89 (1 H, br s; C(O)OCH2
CH), 3.73–3.65 (2 H, m; CH2OH), 2.24–2.16 ppm (2 H, m; CH2C=
C); elemental analysis calcd (%) for C16H20N2O5·0.51,4-dioxane·0.5H2O:
C 57.90, H 6.75, N 7.50; found: C 57.87, H 6.62, N 7.43; ESI-TOF-MS
(positive): m/z : 321.2 [M+H]+ .
(4S)-4-[(4R)-4-(Benzyloxycarbonyamino)-5-hydroxypentyl]oxazolidine-2-
one (19): Compound 18 (123 mg, 0.384 mmol) was dissolved in MeOH
(4 mL) and Pd/C (120 mg) was added to the resulting solution. The reac-
tion mixture was stirred for 1 day under a H2 atmosphere. Pd/C was re-
moved by membrane filtration and the solution was concentrated in
vacuo. The residue was dissolved in 1,4-dioxane (2 mL), and then ZCl
(82 mL, 0.576 mmol) and NaHCO3 aq. (129 mg, 1.54 mmol, l2 mL) were
added. The reaction mixture was stirred for 1.5 h. After this time, the re-
action was extracted with CHCl3. The organic layer was washed with sa-
turated NaHCO3 aq. and brine, dried over Na2SO4, and then concentrat-
ed in vacuo. The residue was purified by silica-gel flash chromatography
(7 g, CHCl3/acetone 2:1) to give 19 (97 mg, 79%).
1H NMR (500 MHz,
CDCl3): d =7.35–7.28 (5 H, m; C6H5), 5.09 (2 H, s; CH2Ph), 4.44 (1 H,
m; C(O)OCH2CH), 3.96 (1 H, m; C(O)OCH2CH), 3.84 (1 H,
br s; C(O)OCH2CH), 3.65–3.63 (3 H, m; CHCH2OH), 1.60–
1.25 ppm (6 H, m; CH2CH2CH2); elemental analysis calcd (%) for
C16H22N2O5·0.4 1,4-dioxane·0.2H2O: C 58.52, H 7.14, N 7.76; found: C
58.50, H 7.14, N 7.83; ESI-TOF-MS (positive): m/z : 323.2 [M+H]+ .
(4S)-4-[(4R)-4-(Benzyloxycarbonyamino)-4-(carboxy)pentyl]oxazolidine-
2-one (20): RuCl3·nH2O (56 mg, 0.27 mmol) and NaIO4 (1.9 g,
8.98 mmol) were dissolved in acetone (3 mL) and H2O (3 mL) at 18 8C.
A solution of 19 (290 mg, 0.898 mmol) in acetone (3 mL) was then added
dropwise and the reaction mixture was stirred for 20 min at 18 8C. After
this time, 2-propanol (4 mL) was added to the reaction mixture and it
was stirred for a further 1 h. Insoluble matter was removed by Celite fil-
tration, and the filtrate was extracted with CHCl3. The organic layer was
washed with 10% citric acid aq. and brine, dried over Na2SO4, and then
concentrated in vacuo to give crude carboxylic acid 20.
(4S)-4-[(4R)-4-(Benzyloxycarbonyamino)-4-(methyloxycarbonyl)pentyl]-
oxazolidine-2-one (21): AcCl (639 mL, 8.98 mmol) was added dropwise to
MeOH (6 mL) at 0 8C. The solution was stirred for 30 min at RT. After
this time, a solution of 20 (0.898 mmol) in MeOH (3 mL) was added and
the reaction mixture was stirred for a further 2 h. After this time, the so-
lution was concentrated in vacuo and the residue was purified by using a
Biotage column (7 g, CHCl3/acetone 10:1) to give 21 (284 mg, 89%).
1H NMR (500 MHz, CDCl3): d=7.35–7.28 (5 H, m; C6H5), 5.09 (2 H, s;
CH2Ph), 4.44 (1 H, m; C(O)OCH2CH), 3.96 (1 H, m; C(O)O
CH2CH), 3.84 (1 H, br s; C(O)OCH2CH), 3.65–3.63 (3 H, m; CH-
CH2OH), 1.60–1.25 ppm (6 H, m; CH2CH2CH2); elemental analysis
calcd (%) for C17H22N2O6·0.51,4-dioxane·0.5H2O: C 56.57, H 6.75, N
6.94; found: C 56.57, H 6.63, N 6.91; ESI-TOF-MS (positive): m/z : 351.19
[M+H]+ .
(4S)-4-[(4R)-4-(Benzyloxycarbonyamino)-4-(methyloxycarbonyl)pentyl]-
3-N-tert-butoxycarbonyloxazolidine-2-one (22): Compound 21 (128 mg,
0.37 mmol) was dissolved in THF (4 mL). DMAP (13 mg, 0.11 mmol),
triethylamine (102 mL, 0.73 mmol), and Boc2O (119 mL, 0.55 mmol) were
then added to the THF solution, and the reaction mixture was stirred for
1 h. After this time, the reaction was extracted with CHCl3 and the re-
sulting organic layer was washed with 10% citric acid and brine, dried
over Na2SO4, and then concentrated in vacuo. The residue was purified
by silica-gel flash chromatography (toluene/AcOEt: 3:1) to give 22
(142 mg, 86%). 1H NMR (500 MHz, CDCl3): d=7.38–7.26 (5 H, m;
C6H5), 5.29 (1 H, d, J =7.5 Hz; NH), 5.11 (2 H, s; CH2Ph), 4.39–4.38
(1 H, m; CHCOOMe), 4.28 (1 H, t, J =8.3 Hz; CHCH2O), 4.20–
4.17 (1 H, m; CHCH2O), 3.97 (1 H, d, J=6.5 Hz; NCHCH2),
3.74 (3H, s; CH3), 1.91–1.83 (2H, m; CH2), 1.74–1.65 (2H, m; CH2),
1.53 ppm (9 H, s; C ACHTUNGTRENNUNG(CH3)3); elemental analysis calcd (%) for
C22H30N2O8·0.5 dioxane·0.15 H2O: C 57.97, H 6.95, N 5.63; found: C
57.94, H 6.85, N 6.22; ESI-TOF-MS (positive): m/z : 473.23 [M+Na]+ .
Benzyl (2R,6S)-2-(benzyloxycarbonylamino)-6-(tert-butoxycarbonylami-
no)-7-hydroxylheptanoate (24): LiOH·H2O aq. (31 mg, 0.74 mmol, 2 mL)
was added dropwise to a solution of 22 (341.6 mg, 0.758 mmol) in THF
(6 mL), and the resulting mixture was stirred for 1 h. After this time,
LiOH·H2O aq. (31 mg, 0.74 mmol, 2 mL) was again added dropwise to
the reaction mixture, and it was stirred for a further 1 h. Then, more
LiOH·H2O aq. (31 mg, 0.74 mmol, 2 mL) was added dropwise to the re-
action mixture, and it was stirred for a final 1 h. The reaction mixture
was then quenched by Dowex H+ . The Dowex H+ was removed by fil-
tration and the filtrate was concentrated in vacuo. The residue was
freeze-dried with 1,4-dioxane to give crude 23, which was then dissolved
in MeOH (8 mL). Cs2CO3 (148 mg, 0.455 mmol) was added to the solu-
tion and it was concentrated in vacuo and then co-evaporated with tolu-
ene. The residue was dissolved in dry DMF (8 mL) and BnBr (108 mL,
0.910 mmol) was added to the solution. The resulting reaction mixture
was stirred for 1 day under an Ar atmosphere. After this time, the reac-
tion mixture was extracted with AcOEt and the resulting organic layer
was washed with 10 % citric acid aq. and brine, dried over Na2SO4, and
then concentrated in vacuo. The residue was purified by silica-gel flash
chromatography (toluene/AcOEt 2:1) to give 24 (313 mg, 83%).
1H NMR (500 MHz, CDCl3): d=7.38–7.29 (10 H, m; C6H5  2), 5.40–5.39
(1 H, br d; NH), 5.19 (1 H, d, J=12 Hz; COOCH2Ph), 5.14 (1 H, d, J=
12 Hz; COOCH2Ph), 5.10 (2 H, s; NHCOOCH2Ph), 4.72 (1 H, br s;
NH), 4.45–4.41 (1 H, m; CHCOOBn), 3.57–3.46 (3 H, m; CH
CH2OH), 1.87–1.30 (6 H, m;ACHTUNGTRENNUNG(CH2)3), 1.43 ppm (9 H, s;C ACHTUNGTRENNUNG(CH3)3); ele-
mental analysis calcd (%) for C27H36N2O7·0.15 H2O: C 64.43, H 7.27, N
5.57; found: C 64.43, H 7.27, N 5.57; ESI-TOF-MS (positive): m/z : 501.2
[M+H]+ .
7-Benzyl (2R,6S)-2-N-benzyloxycarbonyl-6-N-tert-butoxycarbonylamino-
diaminopimelate (25): Compound 24 (301 mg, 0.60 mmol) and PDC
(1.1 g, 3.0 mmol) were dissolved in dry DMF (6 mL) and the resulting
mixture was stirred for 1 day under an Ar atmosphere. After this time,
the reaction mixture was extracted with Et2O and the resulting organic
layer was washed with 10% citric acid aq. and brine, dried over Na2SO4,
and then concentrated in vacuo. The residue was purified by silica-gel
flash chromatography (CHCl3/MeOH 10:1 and CHCl3/MeOH/AcOH
5:1:0.01) to give 25 (264 mg, 86%). 1H NMR (500 MHz, CDCl3): d=
7.34–7.27 (10 H, m; ArH 2), 5.42 (1 H, br s; NH), 5.19 (1 H, d, J =12 Hz;
COOCH2Ph), 5.14 (1 H, d, J =12 Hz; COOCH2Ph), 5.10 (2 H, s; NH
COOCH2Ph), 4.40 (1 H, br s; aH), 4.24 (1 H, br s; aH), 1.91–1.31 (6 H, m;
ACHTUNGTRENNUNG(CH2)3), 1.44 ppm (9 H, s; C ACHTUNGTRENNUNG(CH3)3); elemental analysis calcd (%) for
C27H34N2O8·0.4 H2O: C 62.15, H 6.72, N 5.37; found: C 62.18, H 6.68, N
5.33; ESI-TOF-MS (positive): m/z : 515.2 [M+H]+ .
Protected g-d-Glu-meso-DAP (26): Compound 17 (500 mg, 0.83 mmol)
was dissolved in 50% TFA in CH2Cl2 (4 mL) and the resulting reaction
mixture was stirred for 10 min. After this time, the reaction mixture was
concentrated and then co-evaporated in toluene. Addition of 1 m HCl
ether solution gave a white solid. The supernatant was removed by de-
cantation to give Boc-deprotected 17. WSCD·HCl (168 mg, 1.08 mmol)
and triethylamine (265 mL, 1.90 mmol) were added to a solution of the
Boc-deprotected 17, benzyl tert-butoxycarbonyl glutamate (279 mg,
0.83 mmol), and HOBt (146 mg, 1.08 mmol) in dry THF (8 mL). The re-
action mixture was stirred for 1 day under an Ar atmosphere before
being extracted with AcOEt. The organic layer was washed with 10 %
citric acid solution, saturated aq. NaHCO3, and brine, dried over Na2SO4,
and then concentrated in vacuo. The residue was purified by silica-gel
flash column chromatography (toluene/AcOEt 3:1) to give 26 (546 mg,
83%). 1H NMR (500 MHz, CDCl3): d=7.36–7.28 (20 H, m; C6H5  4),
6.57 (1 H, d, J= 7 Hz; NH), 5.28 (2 H, br s; NH  2), 5.17–5.09 (8 H, m;
CH2Ph  4), 4.54 (1 H, td, J =6.88, 5.5 Hz; DAP 2-H), 4.40–4.34 (2 H,
m; Glu aH, DAP 6-H), 2.25–2.21 (2 H, m; Glu-g-CH2), 2.18–2.12 (1 H, m;
Glu-bCH2), 1.92–1.87 (1 H, m; Glu-bCH2), 1.83–1.58 (4 H, m; DAP 3-
CH2, 5-CH2), 1.41 (9 H, s; CACHTUNGTRENNUNG(CH3)3), 1.39–1.23 ppm (2 H, m; DAP 4-
CH2); ESI-TOF-MS (positive): m/z : 824.37 [M+H]
+ .
Protected l-Ala-g-d-Glu-meso-DAP 27: Compound 26 (304.6 mg,
0.37 mmol) was dissolved in TFA (3 mL) and stirred for 20 min. After
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this time, the reaction mixture was concentrated in vacuo and 1m HCl
ether solution was added to the residue to a give white solid. The super-
natant was removed by decantation to give Boc-deprotected 26.
WSCD·HCl (75 mg, 0.48 mmol) and triethylamine (129 mL, 0.93 mmol)
were added to a solution of Boc-deprotected 26, tert-butoxycarbonyl l-
alanine (70 mg, 0.37 mmol), and HOBt (65 mg, 0.48 mmol) in dry THF
(4 mL). The reaction was stirred for 3 h under an Ar atmosphere. After
this time the reaction mixture was extracted with AcOEt and the result-
ing organic layer was washed with 10 % citric acid solution, saturated aq.
NaHCO3 and brine, dried over Na2SO4, and concentrated in vacuo. The
residue was purified by silica-gel flash column chromatography (toluene/
AcOEt 1:1) to give 27 (319 mg, 96%). 1H NMR (500 MHz, CDCl3): d=
7.34–7.27 (20 H, m;C6H5  4), 7.16 (1 H, d, J =5.5 Hz; NH), 5.45 (1 H, d,
J =5 Hz; NH), 5.16–5.06 (8 H, m; CH2Ph  4), 4.93 (1 H, br s; NH),
4.53 (1 H, dd, J =8, 13 Hz; DAP 2-H), 4.48 (1 H, br s; Glu-aH), 4.36 (1 H,
dd, J= 8, 13 Hz; DAP 6-H), 4.10–4.08 (1 H, m; Ala-aH), 2.28–2.15 (3 H,
m; Glu-gH, Glu-bH), 2.04 (1 H, br s; Glu-bH), 1.86–1.61 (4 H, m; DAP 3-
CH2, 5-CH2), 1.42 (9 H, s; C ACHTUNGTRENNUNG(CH3)3, 1.40–1.32 (2 H, m; DAP 4-CH2),
1.26 ppm (3 H, d, J=5.5 Hz; Ala-bCH3); ESI-TOF-MS (positive): m/z :
895.4 [M+H]+ .
Protected H-l-Ala-g-d-Glu-meso-DAP 28 : Compound 27 (46.5 mg,
0.052 mmol) was dissolved in TFA (400 mL) and the resulting mixture
was stirred for 25 min. After this time, the reaction mixture was concen-
trated in vacuo and 1 m HCl ether solution was added to the residue to
give a white solid. The supernatant was removed by decantation to give
28 (0.052 mmol). The compound was used without further purification.
Protected meso-DAP-d-Ala 29 : WSCD·HCl (116 mg, 0.746 mmol) and
triethylamine (200 mL, 1.44 mmol) were added to a solution of 25
(295 mg, 0.574 mmol), HCl·H-l-Ala-OBn (136 mg, 0.631 mmol), and
HOBt (101 mg, 0.746 mmol) in dry THF (6 mL). The reaction mixture
was stirred for 1 day under an Ar atmosphere. After this time, the reac-
tion mixture was extracted with AcOEt and the resulting organic layer
was washed with 10 % citric acid solution, saturated aqueous NaHCO3,
and brine, dried over Na2SO4, and then concentrated in vacuo. The resi-
due was purified by silica-gel flash column chromatography (CHCl3/ace-
tone 20:1) to give 29 (347,7 mg, 90%). 1H NMR (500 MHz, CDCl3): d=
7.36–7.28 (15 H, m; C6H5  3), 6.63 (1 H, br s; NH), 5.39 (1 H, d, J=
7.5 Hz; NH), 5.19–5.07 (6 H, m; CH2Ph  3), 4.96 (1 H, br s; NH), 4.58
(1 H, m; DAP 2-H), 4.39 (1 H, d, J= 5.5 Hz; DAP 6-H), 4.05 (1 H, br s;
Ala-aH), 1.89–1.53 (6 H, m; DAP ACHTUNGTRENNUNG(CH2)3), 1.43 (9 H, s; C ACHTUNGTRENNUNG(CH3)3),
1.39 ppm (3 H, d, J=7.5 Hz; Ala-bCH3); elemental analysis calcd (%) for
C37H45N3O9·0.6 H2O: C 64.73, H 6.78, N 6.12; found: C 64.33, H 6.42, N
6.39; ESI-TOF-MS (positive): m/z : 676.3 [M+H]+ .
Protected H-l-Ala-g-d-Glu-meso-DAP-d-Ala 30 : Compound 29 (328 mg,
0.486 mmol) was dissolved in TFA (4 mL) and the mixture was stirred
for 1 h. After this time, the reaction mixture was concentrated and then
co-evapolated in toluene ( 2). 1m HCl ether solution was added to the
residue and the mixture was evaporated in vacuo. The residue was
freeze-dried by using 1,4-dioxane to give an oil. WSCD·HCl (98 mg,
0.632 mmol) and triethylamine (169 mL, 1.22 mmol) were added to a solu-
tion of the oil, Boc-d-Glu-OBn (180 mg, 0.535 mmol), and HOBt (85 mg,
0.632 mmol) in dry THF (5 mL). The reaction mixture was stirred for
24 h under an Ar atmosphere, after which time, it was extracted with
AcOEt. The organic layer was washed with 10% citric acid solution, sa-
turated aqueous NaHCO3, and brine, dried over Na2SO4, and then con-
centrated in vacuo. The residue was purified by silica-gel flash column
chromatography (CHCl3/acetone 10:1) to give fully protected g-d-Glu-
meso-DAP-d-Ala (416.4 mg, 96%). 1H NMR (500 MHz, CDCl3): d=
7.38–7.27 (20 H, m; Ph  4), 7.01 (1 H, br s; NH), 6.22 (1 H, br s; NH),
5.44 (1 H, br s; NH), 5.31 (1 H, br s; NH), 5.19–5.06 (8 H, m; CH2Ph
 4), 4.56 (1 H, m; DAP 2-H), 4.38–4.30 (3 H, m; Ala-aH, Glu-aH, DAP
6-H), 2.28–2.15 (3 H, m; Glu-gH, Glu-bH), 1.88–1.64 (5 H, m; Glu-bH,
DAP 3-CH2, 5-CH2), 1.40 (9 H, s; C ACHTUNGTRENNUNG(CH3)3), 1.35 (3 H, d, J =7 Hz; Ala-
bCH3), 1.27–1.23 ppm (2 H, m; DAP-4-CH2); elemental analysis calcd
(%) for C49H58N4O12·H2O: C 64.46, H 6.62, N 6.14; found: C 64.66, H
6.54, N 6.31; ESI-TOF-MS (positive): m/z : 895.4 [M+H]+ .
The fully protected g-d-Glu-meso-DAP-d-Ala (322 mg, 0.36 mmol) was
dissolved in TFA (2 mL) and stirred for 40 min. The reaction mixture
was concentrated and co-evaporated in toluene ( 2). 1 m HCl ether solu-
tion was added to the residue to give white solid, and the supernatant
was removed by decantation. WSCD·HCl (73 mg, 0.468 mmol) and tri-
ethylamine (125 mL, 0.900 mmol) were added to a solution of the residue,
Boc-l-Ala-OBn (75 mg, 0.396 mmol), and HOBt (63 mg, 0.468 mmol) in
dry DMF (4 mL). The reaction was stirred for 1 day under an Ar atmos-
phere. The reaction was extracted with AcOEt and the resulting organic
layer was washed with 10% citric acid solution, saturated aqueous
NaHCO3, and brine, dried over Na2SO4, and then concentrated in vacuo.
The residue was purified by silica-gel flash column chromatography
(CHCl3/acetone 5:1) to give fully protected l-Ala-g-d-Glu-meso-DAP-d-
Ala (277 mg, 80%). 1H NMR (500 MHz, CDCl3): d=7.36–7.28 (20 H, m;
C6H5  4), 7.05 (1 H, br s; NH), 7.05 (1 H, br s; NH), 5.43 (1 H, d, J =6 Hz;
NH), 5.18–5.05 (8 H, m; CH2Ph  4), 4.91 (1 H, br s; NH), 4.57 (1 H, m,
J =7.5 Hz; DAP 2-H), 4.51–4.36 (3 H, m; Glu-aH, d-Ala-aH, DAP 6-H),
4.12–4.05 (1 H, m; l-Ala-aH), 2.40 (1 H, br s; NH), 2.25–2.15 (3 H, m;
Glu-gCH2, Glu-bCH2), 1.94–1.63 (5 H, m; Glu-bCH2, DAP 3-CH2, 5-
CH2), 1.45–1.21 (2 H, m; DAP 4-CH2), 1.42 (9 H, s; C ACHTUNGTRENNUNG(CH3)3), 1.37 (3 H,
d, J= 7 Hz; d-Ala-bCH3), 1.27 (3 H, d, J= 7 Hz; L-Ala-bH); elemental
analysis calcd (%) for C52H63N5O13·H2O: C 63.46, H 6.66, N 7.12; found:
C 63.55, H 6.52, N 7.33; ESI-TOF-MS (positive): m/z : 966.4 [M+H]+ .
The fully-protected l-Ala-g-d-Glu-meso-DAP-d-Ala (28 mg,
0.0285 mmol) was dissolved in TFA (200 mL) and stirred for 20 min. The
reaction mixture was concentrated in vacuo and 1m HCl ether solution
was added to the resulting residue to give a white solid. The supernatant
was removed by decantation to give 30 (0.0285 mmol). The compound
was used without further purification.
1,6-Anhydro-2-azide-4-O-benzyl-2-deoxy-3-O-[(1R)-1-(ethyoxycarbonyl)-
ethyl]-b-d-glucopyranose (32): Tf2O (5.1 mL, 0.027 mol) was added drop-
wise to a solution of (S)-LacOEt (3.2 g, 0.027 mol) and 2,6-lutidine
(3 mL, 0.027 mol) in CH2Cl2 (50 mL) at 70 8C under an Ar atmosphere.
The reaction mixture was stirred for 2 h at RT. Hexane (30 mL) was
added to the solution, and the mixture was purified by silica-gel column
chromatography (silica-gel 150 g, hexane/CH2Cl2 1:1) to give lactic tri-
flate. NaH (1.3 g, 0.027 mol) was added to the CH2Cl2 solution of 31 (5 g,
0.018 mol) under an Ar atmosphere, and the mixture was stirred for
15 min. After this time, lactic triflate was added to the reaction mixture
and it was stirred for a further 1 h. The reaction was quenched with ice
and the organic layer was washed with saturated aqueous NaHCO3 and
brine, dried over Na2SO4, and concentrated in vacuo. The residue was pu-
rified by silica-gel flash column chromatography (CHCl3/acetone 100:1)
to give 32 (5.2 g, 78%); ESI-TOF-MS (positive): m/z : 777.32 [2M+Na]+ .
2-Acetylamino-1,6-anhydro-2-deoxy-4-O-benzyl-3-O-[(1R)-1-(ethyoxycar-
bonyl)ethyl]-b-d-glucopyranose (33): Zn powder was added to a solution
of 32 (1 g, 2.65 mmol) in AcOH/THF 1:1 (4 mL) at 0 8C, and the resulting
mixture was stirred for 10 min. After this time, the Zn powder was re-
moved by filtration and the filtrate was concentrated in vacuo. The resi-
due was dissolved in Ac2O/pyr 1:1 (20 mL), and the reaction mixture was
stirred for a further 45 min. The reaction mixture was evaporated in
vacuo and the residue was extracted with AcOEt. The organic layer was
washed with 1 m HCl aq. and brine, dried over Na2SO4, and concentrated
in vacuo. The residue was purified by silica-gel flash column chromatog-
raphy (toluene/AcOEt 2:1) to give 33 (786 mg, 79%). 1H NMR
(500 MHz, CDCl3): d =7.39–7.33 (5 H, m; ArH), 6.30 (1 H, d, J =8.5 Hz;
NH), 5.35 (1 H, s; H-1), 4.68 (1 H, d, J= 12 Hz; PhCH2O), 4.59 (1 H, d,
J =12 Hz; PhCH2O), 4.56 (1 H, s; H-5), 4.24–4.18 (3 H, m; Lac-aH,
COOCH2CH3), 3.72 (1 H, dd, J =6.7 Hz; H-6’), 3.48–3.46 (1 H, m; H-3),
3.42 (1 H, s; H-4), 1.94 (3 H, s; NHAc), 1.38 (3 H, d, J =7 Hz; Lac-bCH3),
1.29 ppm (3 H, t, J=7 Hz; COOCH2CH3); ESI-TOF-MS (positive):
m/z : 394.1 [M+H]+ .
2-Acetylamino-1,6-anhydro-2-deoxy-4-O-benzyl-3-O-[(1R)-1-(carboxyl)-
ethyl]-b-d-glucopyranose (34): Compound 33 (75 mg, 0.19 mmol) was dis-
solved in THF/1,4-dioxane/H2O 2:1:0.5 (2 mL). LiOH·H2O (9 mg,
0.21 mmol) was added to the reaction mixture and it was stirred for 1.5 h.
After this time, the reaction mixture was quenched with Dowex H+ ,
which was subsequently removed by filtration. The mixture was then con-
centrated in vacuo and the resulting residue was purified by silica-gel
flash column chromatography (CHCl3/MeOH 20:1) to give 34 (30.1 mg,
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44%). 1H NMR (500 MHz, CDCl3): d= 7.43–7.33 (5 H, m; ArH), 6.14
(1 H, d, J=5 Hz; NH), 5.45 (1 H, s; H-1), 4.68 (1 H, d, J= 12 Hz; PhCH2
O), 4.66–4.64 (1 H, m; H-5), 4.59 (1 H, d, J=12 Hz; PhCH2O), 4.26–
4.21 (1 H, m; Lac-aH), 4.18 (1 H, d, J=7.5 Hz; H-6), 4.19–4.11 (1 H, m;
H-2), 3.80–3.76 (1 H, m; H-6’), 3.55 (1 H, s; H-3), 3.44 (1 H, s; H-4), 1.95
(3 H, s; NHAc), 1.39 ppm (3 H, s; Lac-bCH3); ESI-TOF-MS (positive):
m/z : 364.1 [MH] .
2-Trichloroethoxycarbonylamino-1,6-anhydro-2-deoxy-4-O-[(1R)-1-
(ethyoxycarbonyl)ethyl]-b-d-glucopyranose (36): Pd(OH)2 (60 mg) was
added to a solution of 32 (50.7 mg, 0.13 mmol) in THF (1 mL) and the re-
action mixture was stirred for 2 days under a H2 atmosphere
(15 kg cm2). After this time, the Pd(OH)2 was removed by membrane fil-
tration, and the filtrate was concentrated in vacuo. The resulting residue,
TrocCl (22 mL, 0.16 mmol), and triethylamine (28 mL, 0.20 mmol) were
then dissolved in CH2Cl2 (1 mL) and stirred for 15 min. The reaction mix-
ture was extracted with CHCl3. The organic layer was washed with satu-
rated aqueous NaHCO3, dried over Na2SO4, and concentrated in vacuo.
The residue was purified by silica-gel flash column chromatography (tolu-
ene/AcOEt 5:1) to give 36 (44.4 mg, 77%). 1H NMR (500 MHz, CDCl3):
d=5.67 (1 H, d, J=9 Hz; H-1), 5.44 (1 H, s; NH), 4.73 (2 H, dd, J =12,
21 Hz; CH2CCl3), 4.52 (1 H, br s; H-5), 4.24–4.18 (4 H, m; Lac-aH,
COOCH2CH3, H-6), 3.91 (1 H, d, J=9.2 Hz; H-2), 3.80–3.76 (2 H, m;





anoside (38): TMSOTf (5 mL, 0.030 mmol) was added to the solution of
glucosamine imidate 37 (200 mg, 0.296 mmol), 36 (193.6 mg, 0.443 mmol),
and MS (4 ) in dry CH2Cl2 (3 mL) at 17 8C, and the mixture was
stirred for 30 min under an Ar atmosphere. After this time, the reaction
was quenched with saturated aqueous NaHCO3 and the organic layer
was washed with brine, dried over Na2SO4, and then concentrated in
vacuo. The residue was purified by silica-gel flash column chromatogra-
phy (toluene/AcOEt 7:1) to give 38 (182 mg, 65 %). 1H NMR (500 MHz,
CDCl3): d=7.52–7.18 (10 H, m; ArH  2), 5.60 (1 H, s; PhCH=O2), 5.33
(1 H, s; Hanh-1), 5.03 (1 H, d, J =7.7 Hz; NH), 4.91 (1 H, d, J =12 Hz;O
CH2Ph), 4.82 (1 H, d, J =8 Hz; H-1), 4.76 (2 H, dd, J =12, 20 Hz;CH2
CCl3), 4.7 (1 H, d, J= 12 Hz; OCH2Ph), 4.60 (1 H, d, J= 12 Hz; NH),
4.49 (1 H, d, J=5.7 Hz; Hanh-5), 4.33 (1 H, dd, J=5, 10 Hz; H-6), 4.22
(1 H, q, J=3.6 Hz; Lac-aH), 4.20–4.14 (3 H, m; CH2CH3, Hanh-6’), 3.95
(1 H, d, J= 9.8 Hz; Hanh-2), 3.86–3.76 (3 H, m; H-3, H-6, H-4), 3.74–3.72
(2 H, m; Hanh-6’, Hanh-4), 3.58 (1 H, br s; Hanh-3), 3.52–3.42 ppm (2 H, m;
H-2, H-5); elemental analysis calcd (%) for C37H42Cl6N2O14: C 46.71, H




tylamino]-d-glucopyranoside (39): Compound 38 (40.6 mg, 0.0427 mmol)
was dissolved in Ac2O/AcOH/THF 1:1:1 (600 mL). Zn/Cu was added and
the mixture was stirred for 1 h. After this time, the Zn/Cu was removed
by filtration and the filtrate was concentrated in vacuo. The residue was
extracted with AcOEt and the organic layer was washed with saturated
aqueous NaHCO3 and brine, dried over Na2SO4, and then concentrated
in vacuo. The residue was purified by silica-gel flash column chromatog-
raphy (CHCl3/acetone 3:1) to give 39 (23.5 mg, 81%).
1H NMR
(500 MHz, CDCl3): d =7.51–7.31 (10 H, m; ArH  2), 6.77 (1 H, d, J =
9.5 Hz; NH), 5.61 (1 H, s; PhCH=O2), 5.25 (1 H, s; Hanh-1), 5.07 (1 H, d,
J =8 Hz; NH), 4.91 (1 H, d, J =12 Hz; OCH2Ph), 4.67 (1 H, d, J =
12 Hz;OCH2Ph), 4.54 (1 H, d, J =8.5 Hz; H-1), 4.41 (1 H, d, J =5 Hz;
Hanh-5), 4.34 (1 H, dd, J =5, 10.5 Hz; H-6), 4.24–4.16 (5 H, m; Hanh-2,
Hanh-6, Lac-aH, COOCH2CH3), 3.92 (1 H, dd, J =8.5, 13.5 Hz; H-2),
3.82 (1 H, t, J =10.5 Hz; H-6’), 3.78 (1 H, t, J =9.3 Hz; H-4), 3.72 (1 H, s;
Hanh-6’), 3.69 (1 H, t; Hanh-4), 3.63 (1 H, t, J=9.7 Hz; H-3), 3.46 (1 H, s;
Hanh-3), 3.42–3.37 (1 H, m; H-5), 2.09 (3 H, s; NHAc), 1.90 (3 H, s;
NHAc), 1.39 (3 H, d, J =7 Hz; Lac-bCH3), 1.27 (3 H, t, J =3.8 Hz;
COOCH2CH3); elemental analysis calcd for C35H44N2O12·0.4H2O: C
64.33, H 6.81, N 3.33; found: C 64.38, H 6.82, N 3.22; ESI-TOF-MS (posi-
tive): m/z : 685.35 [M+H]+ .
1,6-Anhydro-4-O-(3’-O-benzyl-4’,6’-O-benzylidene-2’-deoxy-2’-acetylami-
no-b-d-glucopyranosyl)-3-O-[(R)-1-(carbonyloxy)ethyl-2-deoxy-2-acetyl-
amino]-d-glucopyranoside (40): Compound 39 (55.2 mg, 0.0806 mmol)
was dissolved in THF/1,4-dioxane/H2O 2:1:0.5. LiOH·H2O (3.7 mg,
0.0887 mmol) was then added to the solution and the reaction mixture
was stirred for 2 h. After this time, the reaction mixture was quenched
with Dowex H+, which was subsequently removed by filtration. The mix-
ture was then concentrated in vacuo and the resulting residue was ap-
plied to an HP-20 column (2  8 cm). Organic and inorganic salts were re-
moved by elution with H2O, followed elution with MeOH to give 40
(45.5 mg, 88%).
Protected disaccharide ACHTUNGTRENNUNG(anh) tetrapeptide 41: WSCD·HCl (7 mg,
0.043 mmol) and triethylamine (14 mL, 0.098 mmol) were added to a solu-
tion of 40 (21.5 mg, 0.033 mmol), tetrapeptide 30, and HOBt (6 mg,
0.043 mmol) in dry DMF (700 mL). The reaction mixture was stirred for
1 day under an Ar atmosphere. After this time, the reaction mixture was
extracted with AcOEt and the organic layer was washed with 10 % citric
acid solution, saturated aq. NaHCO3, and brine, dried over Na2SO4, and
then concentrated in vacuo. The residue was purified by silica-gel flash
column chromatography (CHCl3/acetone 3:2) to give 41 (45.3 mg, 92%).
1H NMR (500 MHz, CDCl3): d=7.84 (1 H, d, J =6 Hz; NH), 7.43–7.27
(30 H, m; ArH 6), 7.08 (1 H, d, J= 8 Hz; NH), 6.93 (1 H, d, J =10.5 Hz;
NH), 5.68 (1 H, d, J =8 Hz; NH), 5.59 (1 H, s; PhCH=O2), 5.30 (1 H, s;
Hanh-1), 5.17–5.05 (10 H, m; CH2Ph), 4.91 (1 H, d, J =12.5 Hz;
OCH2Ph), 4.68 (1 H, d, J=12 Hz; OCH2Ph), 4.53 (1 H, m, J =7 Hz;
d-Ala-aH), 4.45–4.42 (2 H, m; Hanh-5, H-1), 4.38–4.28 (5 H, m; H-6, Lac-
aH, Glu-aH, DAP 2-H, DAP 6-H), 4.22 (1 H, d, J =7 Hz; Hanh-6), 4.12–
4.06 (2 H, m; Hanh-2, l-Ala-aH), 4.03–3.98 (1 H, m; H-2), 3.82–3.70 (4 H,
m; H-6’; H-4, Hanh-6’, Hanh-4), 3.55 (1 H, t, J= 9 Hz; H-3), 3.46 (1 H, s;
Hanh-3), 3.39–3.35 (1 H, m; H-5), 2.41–2.34 (1 H, m; Glu-gCH2), 2.24–2.19
(1 H, m; Glu-gCH2), 2.17–2.11 (1 H, m; Glu-bCH2), 2.10 (3 H, s; NHAc),
1.97–1.94 (1 H, m; Glu-bCH2), 1.91 (3 H, s; NHAc), 1.88–1.61 (4 H, m;
DAP 3-CH2, DAP 5-CH2), 1.49–1.37 (2 H, m; DAP 4-CH2), 1.35 (6 H, d,
J =7 Hz; Lac-bCH3, d-Ala-bCH3), 1.30 ppm (3 H, d, J =6.5 Hz; l-Ala-
bCH3); ESI-TOF-MS (positive): m/z : 1504.61 [M+H]
+ ; HRMS-ESI
QTOF-MS (positive): m/z : calcd for C80H93N7O22: 1526.6272 [M+Na]
+ ;
found: 1526.6249.
Protected disaccharide ACHTUNGTRENNUNG(anh) tripeptide 42 : Compound 42 was synthesized
from 40 and 28, and monosaccharideACHTUNGTRENNUNG(anh) tetrapeptides 43 and 44 were
synthesized from 34 and 30 (for 43) or 28 (for 44), in a manner similar to
the synthesis of 41.
Compound 42 : 1H NMR (500 MHz, CDCl3): d=7.82 (1 H, d, J =6.5 Hz;
NH), 7.42–7.27 (30 H, m; ArH 6), 6.94 (1 H, d, J =9.5 Hz; NH), 5.72
(1 H, d, J =8 Hz; NH), 5.59 (1 H, s; Ph-CH =O2), 5.30 (1 H, s; Hanh-1),
5.15–5.05 (8 H, m; COOCH2Ph  4), 4.91 (1 H, d, J= 12.5 Hz; O
CH2Ph), 4.68 (1 H, d, J =12.5 Hz; OCH2Ph), 4.47 (1 H, td, J =8,
5 Hz; DAP 2-H), 4.43–4.40 (2 H, m; Hanh-5, H-1), 4.35–4.25 (4 H, m; H-6,
Glu-aH, Lac-aH, DAP 6-H), 4.22 (1 H, d, J=7.5 Hz; Hanh-6), 4.10–4.06
(2 H, m; Hanh-2, Ala-aH), 4.00 (1 H, q, J =9 Hz; H-2), 3.81–3.68 (4 H, m;
H-6’, H-4, Hanh-6’, Hanh-4), 3.54 (1 H, t, J =9.5 Hz; H-3), 3.46 (1 H, s; Hanh-
3), 3.40–3.35 (1 H, m; H-5), 2.30–2.12 (4 H, m; Glu-gCH2, Glu-bCH2),
2.09 (3 H, s; NHAc), 1.91 (3 H, s; NHAc), 1.86–1.62 (4 H, m; DAP 3-CH2,
DAP 5-CH2), 1.44–1.39 (2 H, m; DAP 4-CH2), 1.33 (3 H, d, J=7 Hz; Lac-
bCH3), 1.29 ppm (3 H, d, J= 6.5 Hz; Ala-bCH3); ESI-TOF-MS (positive):
m/z : 1434.11 [M+H]+ .
Disaccharide ACHTUNGTRENNUNG(anh) tetrapeptide (TCT, tracheal cytotoxin; 5): Pd(OH)2
(20 mg) was added to a solution of 41 (5.3 mg, 3.52  106 mol) in THF
(300 mL). The reaction mixture was stirred for 1 day under a H2 atmos-
phere (20 kg cm2). After this time, the Pd(OH)2 was removed by mem-
brane filtration, and the filtrate was concentrated in vacuo to give 5
(3.2 mg, quant.). ESI-TOF-MS (positive): m/z : 920.4 [MH] ; HRMS-
ESI QTOF-MS (positive): m/z : calcd for C29H48N6O16: 922.3893 [M+H]
+ ;
found: 922.3898.
Disaccharide ACHTUNGTRENNUNG(anh) tripeptide 6 and monosaccharide ACHTUNGTRENNUNG(anh) tetrapeptides 7
and 8 : Compounds 6, 7, and 8 were synthesized from 42, 43, and 44, re-
spectively, in a manner similar to the synthesis of 5.
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Compound 6 : 1H NMR (500 MHz, CD3OH): d=5.32 (1 H, s; Hanh-1),
4.62 (1 H, d, J =5.5 Hz; H-6), 4.51 (1 H, d, J= 8.5 Hz; H-6’), 4.47–4.42
(1 H, m; Lac-aH), 4.40–4.37 (2 H, m; Glu-aH, DAP 2-H), 4.30 (1 H, d,
J =7 Hz; H-1), 4.12 (1 H, q, J=6.5 Hz; Ala-aH), 3.98 (1 H, s; Hanh-2),
3.91- 3.86 (2 H, m; Hanh-4, Hanh-5), 3.79–3.72 (3 H, m; H-2, H-5, DAP 6-
CH2), 3.71–3.68 (1 H, m; Hanh-6), 3.55 (1 H, br s; Hanh-3), 3.47–3.44 (1 H,
m; H-4), 3.36–3.34 (1 H, m; Hanh-6), 3.32–3.30 (1 H, m; H-3), 2.38–2.33
(2 H, m; Glu-gCH2), 2.23–2.15 (1 H, m; Glu-bCH2), 2.07 (3 H, s; NHAc),
2.03 (3 H, s; NHAc), 1.99–1.92 (1 H, m; Glu-bCH2), 1.87–1.71 (4 H, m;
DAP 3-CH2, DAP 5-CH2), 1.57–1.54 (2 H, m; DAP 4-CH2), 1.42–
1.36 ppm (6 H, m; Lac-bCH3, Ala-bCH3); HRMS-ESI QTOF-MS (posi-
tive): m/z : calcd for C29H48N6O16: 851.3522 [M+H]
+ ; found: 851.3531.
1-Propenyl-2-acetylamino-4,6-O-benzylidene-2-deoxy-3-O-[(R)-1-(ethoxy-
carbonyl)ethyl]-a-d-glucopyranoside (46): H2 activated [IrACHTUNGTRENNUNG(cod)-ACHTUNGTRENNUNG(MePh2P)2]PF6 (38 mg, 0.0445 mmol) in dry THF (2 mL) was added to a
solution of 45 (200 mg, 0.445 mmol) in dry THF (2 mL). After the reac-
tion mixture had been stirred under an Ar atmosphere at RT for 45 min,
it was extracted with AcOEt. The organic layer was washed with saturat-
ed aqueous NaHCO3 and brine, dried over Na2SO4, and then concentrat-
ed in vacuo. The residue was purified by silica-gel flash column chroma-
tography (CHCl3/acetone 50:1) to give 46 (182 mg, 91%). ESI-TOF-MS
(positive): m/z : 450.2 [M+H]+ ; 1H NMR (500 MHz, CDCl3): d=7.47–
7.36 (5 H, m; ArH), 6.10 (1 H, dd, J=12, 1.7 Hz; OCH=CH), 5.59
(1 H, s; PhCH=O2), 5.52 (1 H, d, J= 3 Hz; H-1), 5.14–5.07 (1 H, m, J=
7 Hz; OCH=CH), 4.51 (1 H, q, J =7 Hz; Lac-aH), 4.28–4.15 (4 H, m;
H-4, H-6, COOCH2CH3), 3.89–3.68 (4 H, m; H-2, H-3, H-5, H-6’), 2.05
(3 H, s; NHAc), 1.54 (3 H, dd, J= 7, 1.5 Hz; CH=CHCH3), 1.43 (3 H,
d, J =7 Hz; Lac-bCH3), 1.29 (3 H, t, J=7 Hz;COOCH2CH3).
1-Propenyl-2-acetylamino-4,6-O-benzylidene-2-deoxy-3-O-[(R)-1-(car-
bonyloxy)ethyl]-a-d-glucopyranoside (47): Compound 46 (93.9 mg,
0.209 mmol) was dissolved in THF/1,4-dioxane/H2O 2:1:0.5 (2.1 mL).
LiOH·H2O (10 mg) was added to the solution and the resulting reaction
mixture was stirred for 1 h. After this time, the reaction was quenched
with Dowex H+, which was subsequently removed by filtration. The mix-
ture was then concentrated in vacuo and the resulting residue was puri-
fied by silica-gel flash column chromatography (CHCl3/MeOH 10:1) to
give 47 (90 mg, quant.).
Protected monosaccharide tetrapeptide 48 and protected monosaccharide
tripeptide 49 : Compounds 48 and 49 were synthesized from 47 and 30
(for 48) or 28 (for 49), in a manner similar to the synthesis of 41.
Compound 48 : 1H NMR (500 MHz, CDCl3): d =7.46–7.23 (10 H, m;
ArH), 5.56–5.54 (2 H, br s; PhCH=O2; H-1), 5.17–5.03 (9 H, m; O
CH=CH,CH2Ph  4), 4.56–4.06 (9 H, m; Glu-aH, Lac-aH, DAP 2-H,
DAP 4-H, Ala-aH, d-Ala-aH, H-5, H-2, OCH=CH), 3.87–3.60 (4 H,
m; H-4, H-3, H-6, H-6’), 2.17–1.81 (4 H, m; Glu-bCH2, Glu-gCH2), 1.89
(3 H, s; NHAc), 1.84–1.34 (11 H, m; DAP 3-CH2, DAP 5-CH2, DAP 4-
CH2, Lac-bCH3, Ala-bH, d-Ala-bH), 1.52 ppm (3 H, dd, J= 7, 1.5 Hz;
OCH=CHCH3); ESI-TOF-MS (positive): m/z : 1269.49 [M+H]+ ;
HRMS-ESI QTOF-MS (positive): m/z : calcd for C68H80N6O18: 1291.5427
[M+Na]+ ; found: 1291.5427.
Compound 49 : 1H NMR (500 MHz, CDCl3): d =7.37–7.28 (10 H, m;
ArH), 5.56 (1 H, s; PhCH=O2), 5.51 (1 H, d, J=8 Hz; H-1), 5.12–5.08
(1 H, m; OCH=CH), 5.12–4.38 (4 H, m; Glu-aH, Lac-aH, DAP 2-H,
DAP 4-H), 4.34–4.14 (5 H, m; H-6, H-2, H-4, OCH=CH, Ala-aH),
3.84–3.69 (2 H, m; H-5, H-6’), 2.28–2.06 (4 H, m; Glu-bCH2, Glu-gCH2),
1.89 (3 H, s; NHAc), 1.83–1.59 (4 H, m; DAP 3-CH2, DAP 5-CH2), 1.52
(3 H, dd, J =7, 1.5 Hz; OCH=CHCH3), 1.40–1.38 (2 H, m; DAP 4-
CH2), 1.38 (3 H, d, J=7 Hz; Lac-bCH3), 1.35 (3 H, d, J =6.5 Hz; Ala-
bH); ESI-TOF-MS (positive): m/z : 1198.53 [M+H]+ ; HRMS-ESI QTOF-
MS (positive): m/z : calcd for C65H75N5O17: 1220.5056 [M+Na]
+ ; found:
1220.5055.
1-O-Deprotected monosaccharide tetrapeptide 50 : Compound 48
(4.6 mg, 3.62  106 mol) was suspended in THF/H2O 2:1 (360 mL). I2
(2 mg, 7.25  106 mol) was then added to the solution, and the reaction
mixture was stirred for 30 min. The reaction was quenched by 10%
Na2S2O4 aq. and the mixture was extracted with AcOEt. The organic
layer was washed with 10% Na2S2O4 aq., saturated aqueous NaHCO3,
and brine, dried over Na2SO4, and concentrated in vacuo. The residue
was purified by silica-gel flash column chromatography (CHCl3/MeOH
30:1) to give 50 (4.6 mg, quant.). 1H NMR (500 MHz, CDCl3): d=7.39–
7.27 (20 H, m; ArH), 5.56 (1 H, s; PhCH=O2), 5.26 (1 H, d, J =3 Hz; H-
1), 5.17–5.04 (8 H, m; COOCH2Ph  4), 4.51–4.19 (7 H, m; Glu-aH,
DAP 2-H, DAP 6-H, Lac-aH, Ala-aH, d-Ala-aH, H-4, H-2), 4.14–4.11
(1 H, m; H-2), 3.79–3.63 (3 H, m; H-6, H-6’, H-3), 3.41–3.40 (1 H, m; H-
5), 2.35–1.79 (4 H, m; Glu-bCH2, Glu-g CH2), 1.65–1.57 (4 H, m; DAP 3-
CH2, DAP 5-CH2), 1.95 (3 H, s; NHAc), 1.39–1.32 ppm (8 H, m; DAP 4-
CH2, Lac-bCH3, Ala-bCH3); HRMS-ESI QTOF-MS (positive): m/z :
calcd for C65H76N6O18: 1251.5114 [M+Na]
+ ; found: 1251.5114.
1-O-Deprotected monosaccharide tripeptide 51: Compound 49 (5.6 mg,
4.67  106 mol) was suspended in THF/H2O 2:1 (450 mL). I2 (3 mg, 9.35 
106 mol) was added to the solution, and the reaction mixture was stirred
for 30 min. After this time, the reaction mixture was quenched by 10 %
Na2S2O4 aq. and the mixture was extracted with AcOEt. The organic
layer was washed with 10% Na2S2O4 aq., saturated aqueous NaHCO3,
and brine, dried over Na2SO4, and concentrated in vacuo. The residue
was purified by silica-gel flash column chromatography (CHCl3/MeOH
30:1) to give 51 (4.1 mg, 76%). 1H NMR (500 MHz, CDCl3): d=7.35–
7.26 (20 H, m; ArH), 5.56 (1 H, s; PhCH=O2), 5.34 (1 H, s; H-1), 5.18–
5.05 (8 H, m;COOCH2Ph  4), 4.51–4.15 (7 H, m; Glu-aH, DAP 2-H,
DAP 6-H, Lac-aH, Ala-aH, H-4, H-2), 3.82–3.61 (3 H, m; H-6, H-6’, H-
3), 3.44–3.41 (1 H, m; H-5), 2.35–1.66 (8 H, m; Glu-bCH2, Glu-g CH2,
DAP 3-CH2, DAP 4-CH2, DAP 5-CH2), 1.95 (3 H, s; NHAc), 1.38–
1.32 ppm (6 H, m; Lac-bCH3, Ala-bCH3); ESI-TOF-MS (positive): m/z :
1158.50 [M+H]+ ; HRMS-ESI QTOF-MS (positive): m/z : calcd for
C62H71N5O17: 1180.4743 [M+Na]
+ ; found: 1180.4746.
Monosaccharide tetrapeptide 3 and monosaccharide tripeptide 4 : Com-
pounds 3 and 4 were synthesized from 50 and 51, respectively, in a
manner similar to the synthesis of 5.
Compound 3 : 1H NMR (500 MHz, CDCl3): d =5.10 (1 H, d, J =4 Hz; H-
1), 4.27–4.19 (5 H, m; Glu-aH, DAP 2-H, Ala-aH, d-Ala-aH, Lac-aH),
3.90 (1 H, dd, J =3.5, 11 Hz; H-2), 3.83–3.80 (1 H, m; H-5), 3.77–3.67
(3 H, m; DAP-aH, H-6, H-3), 3.53–3.45 (2 H, m; H-4, H-6’), 2.30–2.27
(2 H, m; Glu-gCH2), 2.14–1.69 (8 H, m; Glu-bCH2, DAP 3-CH2, 5-CH2),
1.92 (3 H, s; NHAc), 1.43–1.39 (2 H, m; DAP 4-CH2), 1.37 (3 H, d, J =
7 Hz; Lac-bH), 1.34–1.30 ppm (6 H, m; Ala-bH, d-Ala-bH); ESI-TOF-
MS (negative): m/z : 735.30 [M+H] ; HRMS-ESI QTOF-MS (positive):
m/z : calcd for C29H48N6O16: 737.3205 [M+Na]
+ ; found: 737.3209.
Compound 4 : 1H NMR (500 MHz, CDCl3): d =5.10 (1 H, d, J =3.5 Hz;
H-1), 4.28–4.21 (4 H, m; Glu-aH, DAP-aH, Ala-aH, Lac-aH), 3.90 (1 H,
dd, J=3.5, 10.5 Hz; H-2), 3.85–3.79 (1 H, m; H-5), 3.77–3.70 (1 H, m;
DAP-aH, H-6), 3.63 (1 H, d, J=10.5 Hz; H-3), 3.53–3.45 (2 H, m; H-4, H-
6’), 2.32–2.21 (2 H, m; Glu-gCH2), 2.18–1.67 (6 H, m; Glu-bCH2, DAP 3-
CH2, 5-CH2), 1.92 (3 H, s; NHAc), 1.43–1.40 (2 H, m; DAP 4-CH2), 1.36
(3 H, d, J =7.5 Hz; Lac-bH), 1.32 ppm (3 H, d, J =6.5 Hz; Ala-bH); ESI-
TOF-MS (negative): m/z : 664.26 [MH] ; HRMS-ESI QTOF-MS (posi-
tive): m/z : calcd for C26H43N5O15: 666.2834 [M+Na]
+ ; found: 666.2837.
1-Allyl 2-acetylamino-6-O-benzyl-4-O-(2’-acetylamino-3’-O-benzyl-4’,6’-
O-benzylidene-2’-deoxy-b-d-glucopyranosyl)-2-deoxy-3-O-[(R)-1-(ethoxy-
carbonyl)ethyl]-a-d-glucopyranoside (53): Zn/Cu (three microspatula
spoonfuls) was added to a solution of 52 (200 mg, 0.182 mmol) in THF/
AcOH/Ac2O 1:1:1 (2 mL), and the mixture was stirred at RT for 3.5 h.
After this time, the insoluble materials were filtered off and the filtrate
was concentrated in vacuo. The residue was extracted with AcOEt and
the organic layer was washed with saturated aqueous NaHCO3 and brine,
dried over Na2SO4, and concentrated in vacuo. The residue was purified
by silica-gel flash column chromatography (toluene/AcOEt 2:1) to give
53 (69 mg, 46%). 1H NMR (500 MHz, CDCl3): d=7.44–7.28 (15 H, m;
ArH), 5.88–5.81 (1 H, m; OCH2CH=CH2), 5.58 (1 H, s; PhCHO2),
5.31–5.30 (1 H, d, J=3 Hz; H-1), 5.25–5.22 (1 H, dd, J =1.5, 17 Hz; O
CH2CH=CHtransHcis), 5.16–5.13 (1 H, dd, J =1.5, 10 Hz; OCH2CH=
CHtransHcis), 4.88 (1 H, d, J =12 Hz; PhCH2O), 4.83 (1 H, d, J =12 Hz;
PhCH2O), 4.65 (1 H, d, J=12 Hz; PhCH2O), 4.35 (1 H, d, J=
12 Hz; PhCH2O), 4.62–4.60 (1 H, m; Lac-aH), 4.45–4.39 (2 H, m; H-
1’, H-6’), 4.26–4.11 (3 H, m; COOCH2CH3, H-6), 3.97–3.92 (2 H, m;
OCH2CH=CH2), 3.78–3.74 (4 H, m; H-2, H-2’, H-4’, H-6’), 3.69–3.44
(6 H, m; H-4’, H-5, H-6, H-3, H-3’, H-4), 3.32–3.27 (1 H, m; H-5’), 2.00
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(3 H, s; NHAc), 1.74 (3 H, s; NHAc), 1.35 (3 H, d, J =7 Hz; Lac-bCH3),




(ethoxycarbonyl)ethyl]-a-d-glucopyranoside (54): H2 activated [Ir ACHTUNGTRENNUNG(cod)-ACHTUNGTRENNUNG(MePh2P)2]PF6 (6.2 mg, 7.31x106 mol) in dry THF (500 mL) was added
to a solution of 53 (60.9 mg, 0.0731 mmol) in dry THF (500 mL). After
the reaction mixture had been stirred under an Ar atmosphere at RT for
2.5 h, the reaction mixture was extracted with AcOEt. The organic layer
was washed with saturated aqueous NaHCO3 and brine, dried over
Na2SO4, and concentrated in vacuo. The residue was purified by silica-gel
flash column chromatography (CHCl3/acetone 15:1) to give 54 (48.6 mg,
80%). 1H NMR (500 MHz, CDCl3): d=7.44–7.28 (15 H, m; ArH), 6.08
(1 H, dd, J=1.5, 12 Hz; OCH=CHCH3), 5.59 (1 H, s; PhCH=O2),
5.50 (1 H, d, J =3.5 Hz; H-1), 5.10–5.04 (1 H, m;OCH=CHCH3), 4.88
(1 H, d, J= 12 Hz; PhCH2O), 4.83 (1 H, d, J =12 Hz; PhCH2O),
4.65 (1 H, d, J=12 Hz; PhCH2O), 4.64–4.60 (1 H, m; Lac-aH), 4.44–
4.40 (2 H, m; H-1’, H-6’), 4.26–4.13 (3 H, m; COOCH2CH3), H-6), 3.96
(1 H, t, J=9 Hz; H-2), 3.78–3.42 (8 H, m; H-3, H-4, H-5, H-6, H-2’, H-3’,
H-4’, H-6’), 3.32–3.27 (1 H, m; H-5’), 1.20 (3 H, s; NHAc), 1.73 (3 H, s;
NHAc), 1.54 (3 H, s; OCH=CHCH3), 1.36 (3 H, d, J =7 Hz; Lac-
bCH3), 1.30 (3 H, t, J =7 Hz; COOCH2CH3); ESI-TOF-MS (positive):
m/z : 833.4 [M+H]+ .
1-Propenyl 2-acetylamino-6-O-benzyl-4-O-(2’-acetylamino-3’-O-benzyl-
4’,6’-O-benzylidene-2’-deoxy-b-d-glucopyranosyl)-3-O-[(R)-1-(carbony-
loxy)ethyl]-2-deoxy-a-d-glucopyranoside (55): Compound 54 (48.6 mg,
5.83  105 mol) was dissolved in THF/1,4-dioxane/H2O 2:1:0.5 (700 mL).
LiOH·H2O (3 mg, 6.42  10
5 mol) was added to the solution and the re-
action mixture was stirred for 3 h. After this time, the reaction was
quenched with Dowex H+ , which was subsequently removed by filtra-
tion. The mixture was then concentrated in vacuo and the resulting resi-
due was applied to an HP-20 column (2  7 cm). Organic and inorganic
salts were removed by elution with H2O, followed by elution with MeOH
to give 55 (41.7 mg, 91%).
Protected disaccharide tetrapeptide 56 and protected disaccharide tripep-
tide 57: Compounds 56 and 57 were synthesized from 55 and 30 (for 56)
or 28 (for 57), respectively, in a manner similar to the synthesis of 41.
Compound 56 : 1H NMR (500 MHz, CDCl3): d =7.40–7.24 (35 H, m;
ArH), 6.06 (1 H, d, J =12.5 Hz; OCH=CHCH3), 5.58 (1 H, s; Ph
CH=O2), 5.27 (1 H, s; H-1), 5.15–5.02 (10 H, m; COOCH2Ph  4,
OCH=CHCH3, H-1’), 4.86 (1 H, d, J =12 Hz; OCH2Ph), 4.75 (1 H,
d, J=12 Hz; OCH2Ph), 4.65 (1 H, d, J =12 Hz; OCH2Ph), 4.58 (1 H,
br s; H-6), 4.52–4.30 (8 H, m; Lac-aH, Ala-aH, d-Ala-aH, Glu-aH, DAP
2-H, DAP 6-H, H-6’ 2), 3.98 (1 H, t, J=10 Hz; H-3’), 3.92–3.90 (1 H, m;
H-2), 3.76 (1 H, t, J= 10.5 Hz; H-4), 3.66–3.58 (5 H, m; H-4’, H-3, H-2’,
H-5, H-6), 3.31–3.26 (1 H, m; H-5), 2.31–2.11 (4 H, m; Glu-bCH2, Glu-
gCH2), 1.94 (3 H, s; NHAc), 1.80 (3 H, s; NHAc), 1.67–1.34 (6 H, m;
DAP 3-CH2, DAP 4-CH2, DAP 5-CH2), 1.48 (3 H, d, J=6.5 Hz; O
CH=CHCH3), 1.38–1.34 ppm (6 H, m; Lac-bCH3, Ala-bCH3); ESI-TOF-
MS (positive): m/z : 1652.67 [M+H]+ .
Compound 57: 1H NMR (500 MHz, CDCl3): d= 7.42–7.21 (35 H, m;
ArH), 6.06 (1 H, d, J =12.5 Hz; OCH=CHCH3), 5.58 (1 H, s; Ph
CH=O2), 5.28 (1 H, d, J =3.5 Hz; H-1), 5.15–5.00 (9 H, m; COOCH2
Ph  4, OCH=CHCH3), 4.86 (1 H, d, J=12 Hz; OCH2Ph), 4.73
(1 H, d, J=12 Hz; OCH2Ph), 4.64 (1 H, d, J= 12 Hz; OCH2Ph),
4.61–4.29 (5 H, m; Lac-aH, Ala-aH, Glu-aH, DAP 2-H, DAP 6-H), 3.97
(1 H, t, J =9.5 Hz; H-5), 3.91 (1 H, dd, J =2.5, 10.5 Hz; H-2), 3.76 (1 H, t,
J =10.5 Hz; H-6’), 3.70–3.60 (2 H, m; H-4, H-4’), 3.59–3.53 (1 H, m; H-3),
3.31–3.26 (1 H, m; H-5’), 2.26–2.00 (4 H, m; Glu-bCH2, Glu-gCH2), 1.94
(3 H, s; NHAc), 1.79 (3 H, s; NHAc), 1.82–1.57 (4 H, m; DAP 3-CH2,
DAP 5-CH2), 1.48 (3 H, dd, J =1.5, 7 Hz; OCH=CHCH3), 1.40–1.34
(2 H, m; DAP 4-CH2), 1.33–1.34 (6 H, m; Lac-bCH3, Ala-bCH3); ESI-
TOF-MS (positive): m/z : 1581.73 [M+H]+ .
1-O-Deprotected disaccharide tetrapeptide 58 and 1-O-deprotected dis-
accharide tripeptide 59 : Compounds 58 and 59 were synthesized from 56
and 57, respectively, in a manner similar to the synthesis of 41.
Compound 58 : 1H NMR (500 MHz, CDCl3): d =7.35–7.24 (35 H, m;
ArH), 5.58 (2 H, br s; PhCH=O2, H-1), 5.15–5.06 (9 H, m; COOCH2
Ph  4, H-1’), 4.87 (1 H, d, J=12 Hz;OCH2Ph), 4.75 (1 H, d, J =12 Hz;
OCH2Ph), 4.64 (1 H, d, J =12 Hz; OCH2Ph), 4.52–4.36 (8 H, m;
Lac-aH, Ala-aH, d-Ala-aH, Glu-aH, DAP 2-H, DAP 6-H, H-6’, O
CH2Ph), 4.02–3.94 (2 H, m; H-6, H-3’), 3.77–3.43 (7 H, m; H-2, H-3, H-4,
H-6, H-2’, H-4’, H-6’), 3.34–3.26 (2 H, m; H-5, H-5’), 2.33–1.97 (4 H, m;
Glu-bCH2, Glu-gCH2), 1.97 (3 H, s; NHAc), 1.72 (3 H, s; NHAc), 1.85–
1.36 (4 H, m; DAP 3-CH2, DAP 4-CH2, DAP 5-CH2), 1.38–1.31 ppm (6 H,
m; Lac-bCH3, Ala-bCH3); ESI-TOF-MS (positive): m/z : 1612.84
[M+H]+ .
Compound 59 : 1H NMR (500 MHz, CDCl3): d =7.40–7.17 (35 H, m;
ArH), 5.58 (2 H, br s; PhCH=O2, H-1), 5.16–5.05 (9 H, m; COOCH2
Ph  4, H-1’), 4.87 (1 H, d, J=12 Hz;OCH2Ph), 4.74 (1 H, d, J =12 Hz;
OCH2Ph), 4.64 (1 H, d, J =12 Hz; OCH2Ph), 4.56–4.34 (9 H, m;
Lac-aH, Ala-aH, Glu-aH, DAP 2-H, DAP 6-H, H-6, H-6’, OCH2Ph),
4.02–3.94 (2 H, m; H-6, H-3’), 3.83–3.43 (7 H, m; H-2, H-3, H-4, H-6, H-
2’, H-4’, H-6’), 3.35–3.31 (1 H, m; H-5), 3.29–3.24 (1 H, m; H-5’), 2.31–
1.98 (4 H, m; Glu-bCH2, Glu-gCH2), 1.96 (3 H, s; NHAc), 1.73 (3 H, s;
NHAc), 1.84–1.32 (6 H, m; DAP 3-CH2, DAP 4-CH2, DAP 5-CH2), 1.39–
1.25 ppm (6 H, m; Lac-bCH3, Ala-bCH3); ESI-TOF-MS (positive): m/z :
1541.79 [M+H]+ .
Disaccharide tetrapeptide 1 and disaccharide tripeptide 2 : Compounds 1
and 2 were synthesized from 58 and 59, respectively, in a manner similar
to the synthesis of 5.
Compound 1: 1H NMR (500 MHz, D2O): d=5.07 (1 H, d, J =3.5 Hz; H-
1), 4.41–4.37 (2 H, m; Ala-aH, H-1’), 4.20–4.03 (5 H, m; Lac-aH, d-Ala-
aH, DAP 2-H, DAP 6-H, Glu-aH), 3.80–3.78 (2 H, m; H-6’ 2), 3.73–3.57
(5 H, m; H-2, H-3, H-4, H-5, H-5’), 3.43–3.39 (1 H, m; H-3’), 3.35–3.27
(3 H, m; H-6  2, H-4’), 2.22–1.94 (4 H, m; Glu-bCH2, Glu-gCH2), 1.90
(3 H, s; NHAc), 1.80 (3 H, s; NHAc), 1.83–1.57 (4 H, m; DAP 3-CH2, 5-
CH2), 1.33–1.25 (2 H, m; DAP 4-CH2), 1.29 (3 H, d, J =7.5 Hz; Lac-
bCH3), 1.25 (3 H, d, J =6.5 Hz; Ala-bCH3), 1.20 (3 H, d, J =7 Hz; d-Ala-
bCH3); ESI-TOF-MS (negative): m/z : 938.31 [MH] ; HRMS-ESI
QTOF-MS (positive): m/z : calcd for C37H61N7O21: 940.3999 [M+H]
+ ;
found: 940.4031.
Compound 2 : 1H NMR (500 MHz, CD3OD): d=5.20 (1 H, br s; H-1),
4.59–4.58 (2 H, m; Ala-aH, H-1’), 4.43–4.42 (4 H, m; Lac-aH, DAP 2-H,
DAP 6-H, Glu-aH), 3.90–3.89 (2 H, m; H-6’ 2), 3.81–3.58 (5 H, m; H-2,
H-3, H-4, H-5, H-5’), 3.43–3.29 (4 H, m; H-3’, H-6  2, H-4’), 2.32- 1.99
(4 H, m; Glu-bCH2, Glu-gCH2), 1.97 (3 H, s; NHAc), 1.95 (3 H, s;
NHAc), 1.80–1.53 (4 H, m; DAP 3-CH2, DAP 4-CH2, DAP 5-CH2), 1.40–
1.28 ppm (6 H, m; Lac-bCH3, Ala-bCH3); ESI-TOF-MS (negative): m/z :
867.37 [MH] ; HRMS-ESI QTOF-MS (positive) m/z : calcd for
C34H56N6O20: 869.3627 [M+H]
+ ; found: 869.3622.
HEK293T Bioassay for Nod1 stimulation : Ligand dependent NF-kB acti-
vation was determined by using 0.5  105 HEK293T cells transfected with
expression plasmids of Nod1 (0.17 ng of pCMV-SPORT6-Nod1), in the
presence of reporter plasmids, NF-kB dependent pBxIV-luc, and control
pEF1BOS-b-gal as described.[7] Briefly, HEK293T cells were transfected
with expression plasmids by the calcium phosphate method, and 8 h after
transfection, cells were treated with a medium containing various ligands.
24 h after transfection, ligand-dependent NF-kB activation was deter-
mined by the luciferase reporter assay.
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